Carcinogenesis in Down syndrome: What can be learned from trisomy 21?

Seminars in Cancer Biology

Volumn 18, Issue 5, 2008, Pages 365-371

  Satgé, Daniel ^a   Bénard, Jean ^b  

^a CENTRE HOSPITALIER   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Carcinogenesis; Constitutional resistance to cancer; Down syndrome; Somatic mutations; Stroma

Indexed keywords

TRANSCRIPTION FACTOR GATA 1;

ACUTE MEGAKARYOCYTIC LEUKEMIA; CANCER RISK; CARCINOGENESIS; CELL MATURATION; CELL PROLIFERATION; CELL TRANSFORMATION; DISEASE ASSOCIATION; DOWN SYNDROME; EXTRACELLULAR MATRIX; GENETIC ASSOCIATION; HUMAN; NEOPLASM; RETINOBLASTOMA; REVIEW; SOMATIC MUTATION; TRISOMY 21;

DOWN SYNDROME; EXTRACELLULAR MATRIX; FIBROBLASTS; GATA1 TRANSCRIPTION FACTOR; HUMANS; LEUKEMIA, MEGAKARYOBLASTIC, ACUTE; MUTATION; NEOPLASMS; STROMAL CELLS;

EID: 48349142492     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2008.03.020     Document Type: Review

References (127)

1. Weinberg R.A. The nature of cancer, and multistep tumorigenesis. In: Taylor and Francis Group (Ed). The biology of cancer (2007), Garland Science, New York 26-56 p. 399-463
2. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat Med 10 (2004) 789-799
3. Prehn R.T. Cancers beget mutations versus mutations beget cancers. Cancer Res 54 (1994) 5296-5300
4. Sonnenschein C., and Soto A.M. The society of cells: cancer and control of cell proliferation (1999), Springer-Verlag, New York
5. Jaffe L.F. Epigenetic theories of cancer initiation. Adv Cancer Res 90 (2003) 209-230
6. Soto A.M., and Sonnenschein C. The somatic mutation theory of cancer: growing problems with the paradigm?. Bioessays 26 (2004) 1097-1107
7. Duesberg P., Li R., Fabarius A., and Hehlmann R. The chromosomal basis of cancer. Cell Oncol 27 (2005) 293-318
8. Stewart T.A., and Mintz B. Successive generations of mice produced from an established culture line of euploid teratocarcinoma cells. Proc Natl Acad Sci USA 78 (1981) 6314-6318
9. Rubin H. What keeps cells in tissues behaving normally in the face of myriad mutations?. Bioessays 28 (2006) 515-524
10. Hochedlinger K., Blelloch R., Brennan C., Yamada Y., Kim M., Chin L., et al. Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev 18 (2004) 1875-1885
11. Kulesa P.M., Kasemeier-Kulesa J.C., Teddy J.M., Margaryan N.V., Seftor E.A., Seftor R.E., et al. Reprogramming metastatic melanoma cells to assume a neural crest cell-like phenotype in an embryonic microenvironment. Proc Natl Acad Sci USA 103 (2006) 3752-3757
12. Lijinsky W. A view of the relation between carcinogenesis and mutagenesis. Environ Mol Mutagen 16 (1989) 78-84
13. Hahn W.C., and Weinberg R.A. Rules for making human tumor cells. N Engl J Med 347 (2002) 1593-1603
14. Smalley K.S., Brafford P.A., and Herlyn M. Selective evolutionary pressure from the tissue microenvironment drives tumor progression. Semin Cancer Biol 15 (2005) 451-459
15. Seguin E. Le traitement moral, l'hygiène et l'éducation des idiots. In: Baillière editor. Paris: JB; 1846.
16. Down J.H.L. Observation on an ethnic classification of idiots. Clin Lect Rep 3 (1866) 259-262
17. Lejeune J., Gautier M., and Turpin R. Study of somatic chromosomes from 9 Mongoloid children. CR Acad Sci 248 (1959) 1721-1722
18. Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T., Park H.S., et al. Chromosome 21 mapping and sequencing consortium. The DNA sequence of human chromosome 21. Nature 405 (2000) 311-319
19. Gardiner K., Davisson M.T., Pritchard M., Patterson D., Groner Y., Crnic L.S., et al. Report on the expert workshop on the biology of chromosome 21: towards gene-phenotype correlations in Down syndrome. Washington, DC, June 11-14, 2004. Cytogenet Genome Res (2005) 269-277 p. 108
20. Satgé D., Sommelet D., Geneix A., Nishi M., Malet P., and Vekemans M.J. A tumor profile in Down syndrome. Am J Med Genet 78 (1998) 207-216
21. Hasle H., Clemmensen I.H., and Mikkelsen M. Risks of leukemia and solid tumours in individuals with Down's syndrome. Lancet 355 (2000) 165-169
22. Satgé D., Sasco A.J., Azema B., and Culine S. Cancers in persons with intellectual deficiency: current data. Mental retardation research focus (2007), Nova Sciences Publisher, New York p. 47-84
23. Satgé D. A decreased incidence of neuroblastomas in Down syndrome and over-production of S-100 b protein: a hypothesis. Med Hypotheses 46 (1996) 393-399
24. Benard J., Beron-Gaillard N., and Satge D. Down's syndrome protects against breast cancer: is a constitutional cell microenvironment the key?. Int J Cancer 113 (2005) 168-170
25. Satgé D, Créau N, Aflalo-Rattenbach R, Ducassou S, Lutz P, Bénard J. Down syndrome's protection against neuroblastoma: the stromal and neural overmaturation tracks. In: Focus on neuroblastoma research. New York: Nova Sciences Publisher; in press.
26. Crispino J.D. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia. Pediatr Blood Cancer 44 (2005) 40-44
27. Zipursky A. Transient leukaemia-a benign form of leukemia in newborn infants with trisomy 21. Br J Haematol 120 (2003) 930-938
28. Wechsler J., Greene M., McDevitt M.A., Anastasi J., Karp J.E., Le Beau M.M., et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 32 (2002) 148-152
29. Groet J., McElwaine S., Spinelli M., Rinaldi A., Burtscher I., Mulligan C., et al. Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder. Lancet 361 (2003) 1617-1620
30. Xu G., Nagano M., Kanezaki R., Toki T., Hayashi Y., Taketani T., et al. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood 102 (2003) 2960-2968
31. Harigae H., Xu G., Sugawara T., Ishikawa I., Toki T., and Ito E. The GATA1 mutation in an adult patient with acute megakaryoblastic leukemia not accompanying Down syndrome. Blood 103 (2004) 3242-3243
32. Rainis L., Bercovich D., Strehl S., Teigler-Schlegel A., Stark B., Trka J., et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood 102 (2003) 981-986
33. Hitzler J.K., and Zipursky A. Origins of leukemia in children with Down syndrome. Nat Rev Cancer 5 (2005) 11-20
34. Pine S.R., Guo Q., Yin C., Jayabose S., Druschel C.M., and Sandoval C. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood 110 (2007) 2128-2131
35. Albertini R.J., Nicklas J.A., and O'Neill J.P. Studies of DNA alterations in in vivo somatic cell mutations in humans. Basic Life Sci 53 (1990) 315-328
36. Ahmed M., Sternberg A., Hall G., Thomas A., Smith O., O'Marcaigh A., et al. Natural history of GATA1 mutations in Down syndrome. Blood 103 (2004) 2480-2489
37. Reamon-Buettner S.M., and Borlak J. TBX5 mutations in non-Holt-Oram syndrome (HOS) malformed hearts. Hum Mutat 24 (2004) 104
38. Reamon-Buettner S.M., and Borlak J. Somatic NKX2-5 mutations as a novel mechanism of disease in complex congenital heart disease. J Med Genet 41 (2004) 684-690
39. Reamon-Buettner S.M., and Borlak J. HEY2 mutations in malformed hearts. Hum Mutat 27 (2006) 118
40. Li C.M., Guo M., Salas M., Schupf N., Silverman W., Zigman W.B., et al. Cell type-specific over-expression of chromosome 21 genes in fibroblasts and fetal hearts with trisomy 21. BMC Med Genet 7 (2006) 24
41. Albertini R.J. HPRT mutations in humans: biomarkers for mechanistic studies. Mutat Res 489 (2001) 1-16
42. Lin Y.W., Perkins J.J., Zhang Z., and Aplan P.D. Distinct mechanisms lead to HPRT gene mutations in leukemic cells. Genes Chromosomes Cancer 39 (2004) 311-323
43. Colgin L.M., Hackmann A.F., Emond M.J., and Monnat Jr. R.J. The unexpected landscape of in vivo somatic mutation in a human epithelial cell lineage. Proc Natl Acad Sci USA 99 (2002) 1437-1442
44. Finette B.A., Rood B., Poseno T., Vacek P., Pueschel S., and Homans A.C. Atypical background somatic mutant frequencies at the HPRT locus in children and adults with Down syndrome. Mutat Res 403 (1998) 35-43
45. Higurashi M., Tada A., Miyahara S., and Hirayama M. Chromosome damage in Down's syndrome induced by chickenpox infection. Pediatr Res 10 (1976) 189-197
46. Shubber E.K., Hamami H.A., Allak B.M., and Khaleel A.H. Sister-chromatid exchanges in lymphocytes from infants with Down's syndrome. Mutat Res 248 (1991) 61-72
47. Preston R.J. X-ray-induced chromosome aberrations in Down lymphocytes: an explanation of their increased sensitivity. Environ Mutagen 3 (1981) 85-89
48. Yotti L.P., Glover T.W., Trosko J.E., and Segal D.J. Comparative study of X-ray and UV induced cytotoxicity, DNA repair, and mutagenesis in Down's syndrome and normal fibroblasts. Pediatr Res 14 (1980) 88-92
49. Ladvocat Bartholomei-Santos M., and de Lucca E.J. Chromosome sensitivity to bleomycin in G2 lymphocytes from Down syndrome patients. Braz J Genet 20 (1997) 79-85
50. Shafik H.M., Au W.W., Whorton Jr. E.B., and Legator M.S. Breakpoints in Down syndrome lymphocytes. Am J Med Genet Suppl 7 (1990) 195-200
51. Maluf S.W., and Erdtmann B. Genomic instability in Down syndrome and Fanconi anemia assessed by micronucleus analysis and single-cell gel electrophoresis. Cancer Genet Cytogenet 124 (2001) 71-75
52. Toki T., Katsuoka F., Kanezaki R., Xu G., Kurotaki H., Sun J., et al. Transgenic expression of BACH1 transcription factor results in megakaryocytic impairment. Blood 105 (2005) 3100-3108
53. Osato M., and Ito Y. Increased dosage of the RUNX1/AML1 gene: a third mode of RUNX leukemia?. Crit Rev Eukaryot Gene Expr 15 (2005) 217-228
54. Crispino J.D. GATA1 in normal and malignant hematopoiesis. Semin Cell Dev Biol 16 (2005) 137-147
55. Aguilera A. The connection between transcription and genomic instability. EMBO J 21 (2002) 195-201
56. Kim N., Abdulovic A.L., Gealy R., Lippert M.J., and Jinks-Robertson S. Transcription-associated mutagenesis in yeast is directly proportional to the level of gene expression and influenced by the direction of DNA replication. DNA Repair (Amst) 6 (2007) 1285-1296
57. Jackson A.L., and Loeb L.A. The mutation rate and cancer. Genetics 148 (1998) 1483-1490
58. Izraeli S. Down's syndrome as a model of a pre-leukemic condition. Haematologica 91 (2006) 1448-1452
59. Mao E.F., Lane L., Lee J., and Miller J.H. Proliferation of mutators in a cell population. J Bacteriol 179 (1997) 417-422
60. Noble D. The music of life. Biology beyond the genome (2006), Oxford University Press, New York
61. Ingber D.E. Cellular mechanotransduction: putting all the pieces together again. FASEB J 20 (2006) 811-827
62. Yang Q., Rasmussen S.A., and Friedman J.M. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet 359 (2002) 1019-1025
63. Holland W.W., Doll R., and Carter C.O. The mortality from leukemia and other cancers among patients with Down's syndrome (mongols) and among their parents. Br J Cancer 16 (1962) 177-186
64. Scholl T., Stein Z., and Hansen H. Leukemia and other cancers, anomalies and infections as causes of death in Down's syndrome in the United States during 1976. Dev Med Child Neurol 24 (1982) 817-829
65. Nishi M., Miyake H., Takeda T., and Hatae Y. Congenital malformations and childhood cancer. Med Pediatr Oncol 34 (2000) 250-254
66. Hermon C., Alberman E., Beral V., and Swerdlow A.J. Mortality and cancer incidence in persons with Down's syndrome, their parents and siblings. Ann Hum Genet 65 (2001) 167-176
67. Boker L.K., Blumstein T., Sadetzki S., et al. Incidence of leukemia and other cancers in Down syndrome subjects in Israel. Int J Cancer 93 (2001) 741-744
68. Hill D.A., Gridley G., Cnattingius S., Mellemkjaer L., Linet M., Adami H.O., et al. Mortality and cancer incidence among individuals with Down syndrome. Arch Intern Med 163 (2003) 705-711
69. Satgé D., Sasco A.J., and Lacour B. Are solid tumours different in children with Down's syndrome?. Int J Cancer 106 (2003) 297-298
70. Patja K., Pukkala E., Sund R., Iivanainen M., and Kaski M. Cancer incidence of persons with Down syndrome in Finland: a population-based study. Int J Cancer 118 (2006) 1769-1772
71. Sullivan S.G., Hussain R., Glasson E.J., and Bittles A.H. The profile and incidence of cancer in Down syndrome. J Intellect Disabil Res 51 (2007) 228-231
72. Mann J.R., Pearson D., Barrett A., Raafat F., Barnes J.M., and Wallendszus K.R. Results of the United Kingdom Children's Cancer Study Group's malignant germ cell tumor studies. Cancer 63 (1989) 1657-1667
73. Satgé D., Sasco A.J., Cure H., Sommelet D., and Vekemans M.J. An excess of testicular germ cell tumors in Down syndrome. Three cases report and literature review. Cancer 80 (1997) 929-935
74. Satge D., and Van Den Berghe H. Aspects of the neoplasms observed in patients with constitutional autosomal trisomy. Cancer Genet Cytogenet 87 (1996) 63-70
75. Wisniewski K.E., Laure-Kamionowska M., and Wisniewski H.M. Evidence of arrest of neurogenesis and synaptogenesis in brains of patients with Down's syndrome. N Engl J Med 311 (1984) 1187-1188
76. Wisniewski K.E. Down syndrome children often have brain with maturation delay, retardation of growth, and cortical dysgenesis. Am J Med Genet Suppl 7 (1990) 274-281
77. Brooksbank B.W., Walker D., Balazs R., and Jorgensen O.S. Neuronal maturation in the foetal brain in Down's syndrome. Early Hum Dev 18 (1989) 237-246
78. Plioplys A.V. Down's syndrome. Precocious neurofilament antigen expression. J Neurol Sci 79 (1987) 91-100
79. Buxhoeveden D., Fobbs A., Roy E., and Casanova M. Quantitative comparison of radial cell columns in children with Down's syndrome and controls. J Intellect Disabil Res 46 (2002) 76-81
80. Buxhoeveden D., and Casanova M.F. Accelerated maturation in brains of patients with Down syndrome. J Intellect Disabil Res 48 (2004) 704-705
81. Allinquant B., Hantraye P., Mailleux P., Moya K., Bouillot C., and Prochiantz A. Downregulation of amyloid precursor protein inhibits neurite outgrowth in vitro. J Cell Biol 128 (1995) 919-927
82. Tanaka M., Ohashi R., Nakamura R., Shinmura K., Kamo T., Sakai R., et al. Tiam1 mediates neurite outgrowth induced by ephrin-B1 and EphA2. EMBO J 23 (2004) 1075-1088
83. Griffin W.S.T., Stanley L.C., Ling C., White L., MacLeod V., Perrot L.J., et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 86 (1989) 7611-7615
84. Kato K., Suzuki F., Kurobe N., Okajima K., Ogasawara N., Nagaya M., et al. Enhancement of S-100β protein in blood of patients with Down's syndrome. J Mol Neurosci 2 (1990) 109-113
85. Kligman D., and Hsieh L.S. Neurite extension factor induces rapid morphological differentiation of mouse neuroblastoma cells in defined medium. Dev Brain Res 33 (1987) 296-300
86. Winningham-Major F., Staecker J.L., Barger S.W., Coats S., and Van Eldik L.J. Neurite extension and neuronal survival activities of recombinant S100 beta proteins that differ in the content and position of cysteine residues. J Cell Biol 109 (1989) 3063-3071
87. Harris H. Tumour suppression: putting on the brakes. Nature 427 (2004) 201
88. Satgé D., Monteil P., Sasco A.J., Vital A., Ohgaki H., Geneix A., et al. Aspects of intracranial and spinal tumors in patients with Down syndrome and report of a rapidly progressing grade 2 astrocytoma. Cancer 91 (2001) 1458-1466
89. Rajpert-de Meyts E., Jorgensen N., Müller J., and Skakkebaek N.E. Prolonged expression of the c-kit receptor in germ cells of intersex fetal testes. J Pathol 178 (1996) 166-169
90. Cools M., Honecker F., Stoop H., Veltman J.D., de Krijger R.R., Steyerberg E., et al. Maturation delay of germ cells in fetuses with trisomy 21 results in increased risk for the development of testicular germ cell tumors. Hum Pathol 37 (2006) 101-111
91. Sperger J.M., Chen X., Draper J.S., Antosiewicz J.E., Chon C.H., Jones S.B., et al. Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors. Proc Natl Acad Sci USA 100 (2003) 13350-13355
92. Niwa H., Miyazaki J., and Smith A.G. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 24 (2000) 372-376
93. Rajpert-De Meyts E., Jorgensen N., Brondum-Nielsen K., Muller J., and Skakkebaek N.E. Developmental arrest of germ cells in the pathogenesis of germ cell neoplasia. APMIS 106 (1998) 198-204
94. Jacobsen G.K., and Henriques U.V. A fetal testis with intratubular germ cell neoplasia (ITGCN). Mod Pathol 5 (1992) 547-549
95. Dada R., Kumar R., and Kucheria K. A 2-year-old baby with Downs syndrome, cryptorchidism and testicular tumour. Eur J Med Genet 49 (2006) 265-268
96. Taktikos A. Association of retinoblastoma with mental defect and other pathological manifestations. Br J Ophthalmol 48 (1964) 495-498
97. Miller R.W. Neoplasia and Down's syndrome. Ann N Y Acad Sci 171 (1970) 637-644
98. Satgé D., Gembara P., Sasco A.J., Francannet C., Desjardins L., Vekemans M., et al. An infant with Down syndrome and retinoblastoma. A possible non-fortuitous association. Ophthalmic Genet 22 (2001) 117-123
99. Satgé D., Schorderet D.F., Balmer A., Beck-Popovic M., Addor M.C., Beckmann J.S., et al. Association Down syndrome-retinoblastoma: a new observation. Ophthalmic Genet 26 (2005) 151-152
100. Liza-Sharmini A.T., Azlan Z.N., and Zilfalil B.A. Ocular findings in Malaysian children with Down syndrome. Singapore Med J 47 (2006) 14-19
101. Gurney J.G., Ross J.A., Wall D.A., Bleyer W.A., Severson R.K., and Robison L.L. Infant cancer in the U.S.: histology-specific incidence and trends, 1973-1992. J Pediatr Hematol Oncol 19 (1997) 428-432
102. Ginsberg J., Bofinger M.K., and Roush J.R. Pathologic features of the eye in Down's syndrome with relationship to other chromosomal anomalies. Am J Ophthalmol 83 (1977) 874-880
103. Ginsberg J., Ballard E.T., Buchino J.J., and Kinkler A.K. Further observations of ocular pathology in Down's syndrome. J Pediatr Ophthalmol Strabismus 17 (1980) 166-171
104. Hermann J., Gilbert E.F., and Opitz J.M. Dysplasia, malformations and cancer. Chromosome anomalies. In: Nichols W.N., and Murphy D.G. (Eds). Proceedings of the workshop on regulation of cell proliferation and differentiation (1975), Plenum Press, New York 19-29
105. Lee M.H., Williams B.O., Mulligan G., Mukai S., Bronson R.T., Dyson N., et al. Targeted disruption of p107: functional overlap between p107 and Rb. Genes Dev 10 (1996) 1621-1632
106. MacPherson D., Sage J., Kim T., Ho D., McLaughlin M.E., and Jacks T. Cell type-specific effects of Rb deletion in the murine retina. Genes Dev 18 (2004) 1681-1694
107. Munier F., Pescia G., Jotterand-Bellomo M., Balmer A., Gailloud C., and Thonney F. Constitutional karyotype in retinoblastoma. Case report and review of literature. Ophthalmic Paediatr Genet 10 (1989) 129-150
108. Allinen M., Beroukhim R., Cai L., Brennan C., Lahti-Domenici J., Huang H., et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6 (2004) 17-32
109. Rizki A., and Bissel M.J. Homeostasis in the breast: it takes a village. Cancer Cell 6 (2004) 1-2
110. Soto A.M., and Sonnenschein C. Emergentism as a default: cancer as a problem of tissue organization. J Biosci 30 (2005) 103-118
111. Bissell M.J., and Rizki A. Putting tumors in context. Nat Rev 1 (2001) 46-54
112. Bénard J. Microenvironment and tumour progression: the concept progresses. Bull Cancer 91 (2004) 663-665
113. Kenny P.A., and Bissell M.J. Tumor reversion: correction of malignant behavior by microenvironmental cues. Int J Cancer 107 (2003) 688-695
114. Bhowmick N.A., Neilson E.G., and Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 432 (2004) 332-337
115. Tlsty T.D., and Hein P.W. Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev 11 (2001) 54-59
116. von Kaisenberg C.S., Krenn V., Ludwig M., Nicolaides K.H., and Brand-Saberi B. Morphological classification of nuchal skin in human fetuses with trisomy 21, 18, and 13 at 12-18 weeks and in a trisomy 16 mouse. Anat Embryol (Berl) 197 (1998) 105-124
117. Raio L., Cromi A., Ghezzi F., Passi A., Karousou E., Viola M., et al. Hyaluronan content of Wharton's jelly in healthy and Down syndrome fetuses. Matrix Biol 24 (2005) 166-174
118. Komatsu T., Kubota E., and Sakai N. Enhancement of matrix metalloproteinase (MMP)-2 activity in gingival tissue and cultured fibroblasts from Down's syndrome patients. Oral Dis 7 (2001) 47-55
119. Zorick T.S., Mustacchi Z., Bando S.Y., Zatz M., Moreira-Filho C.A., Olsen B., et al. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. Eur J Hum Genet 9 (2001) 811-814
120. Maffini M.V., Calabro J.M., Soto A.M., and Sonnenschein C. Stromal regulation of neoplastic development: age-dependent normalization of neoplastic mammary cells by mammary stroma. Am J Pathol 167 (2005) 1405-1410
121. Wright T.C., Orkin R.W., Destrempes M., and Kurnit D.M. Increased adhesiveness of Down syndrome fetal fibroblasts in vitro. Proc Natl Acad Sci USA 81 (1984) 2426-2430
122. Skog J., Mei Y.F., and Wadell G. Human adenovirus serotypes 4p and 11p are efficiently expressed in cell lines of neural tumour origin. J Gen Virol 83 (2002) 1299-1309
123. Barlow G.M., Lyons G.E., Richardson J.A., Sarnat H.B., and Korenberg J.R. DSCAM: an endogenous promoter drives expression in the developing CNS and neural crest. Biochem Biophys Res Commun 299 (2002) 1
124. Satgé D., Sasco A.J., Carlsen N.L.T., Stiller C.A., Rubie H., Hero B., et al. A lack of neuroblastoma in Down syndrome: a study from 11 European countries. Cancer Res 58 (1998) 448-452
125. Cairns J. The origin of human cancers. Nature 289 (1981) 353-357
126. Sonnenschein C., and Soto A.M. Carcinogenesis and metastasis now in the third dimension-what's in it for pathologists?. Am J Pathol 168 (2006) 363-366
127. Baker S.G., and Kramer B.S. Paradoxes in carcinogenesis: new opportunities for research directions. BMC Cancer 7 (2007) 151